Friday’s Big Bounce Potential Watchlist: EPAZ, SKYE, SHMP, BASA

Penny stocks have long been known for their potential to deliver substantial gains, and identifying breakout opportunities within this market can be rewarding. Today, we delve into the realm of penny stocks, focusing on their potential for significant growth and breakout potential.

Within this dynamic landscape, a few standout companies have caught our attention. These companies operate in diverse sectors, ranging from disruptive technologies to biotechnology and sustainable construction materials. While their current market performance may be on the downtrend, these penny stocks possess intriguing qualities that could position them for a potential breakout.

Epazz, Inc. (OTC: EPAZ)

EPAZ has been gaining attention in the tech industry with its mission-critical offerings, including drone technology, blockchain mobile apps, and cloud-based business software solutions. The company’s subsidiaries, Galaxy Batteries Inc. and ZenaDrone Inc., are at the forefront of groundbreaking innovations, positioning Epazz for success and driving its growth prospects.

Last month, it was announced that, as part of its strategic initiatives, Epazz formed Galaxy Batteries Inc. in order to consolidate its intellectual property in the realm of battery technology. 

With a focus on developing specialized batteries for high-powered devices and aircraft, Galaxy Batteries is poised to revolutionize the industry. The company has been diligently working on cutting-edge battery technologies, and its efforts have paved the way for filing patents that could propel Galaxy Batteries into an independent company in the future.

The demands of Epazz’s various projects, like the Zenadrone 1000, which call for highly-powered batteries to operate specialized devices, are what motivate the company’s dedication to battery technology. To establish a strong presence in the battery technology space, Epazz launched as its dedicated platform to showcase its offerings in this field.

Shaun Passley, Ph.D., the CEO of Epazz, stated, “When we embarked on the drone project back in 2019, we couldn’t have foreseen the diverse range of technologies we would need to create. As the project progressed, new opportunities emerged. We are now evaluating the best ways to monetize our technological advancements and create value for our company.”

ZenaDrone Inc.: Intelligent Drone Solutions

Epazz’s subsidiary, ZenaDrone Inc., has been making waves this spring with its flagship product, the ZenaDrone 1000. This advanced unmanned aerial vehicle (UAV) has captured the interest of various sectors, including Native American tribes, after its appearance in May at the RES 2023 event in Las Vegas. ZenaDrone Inc. showcased how the ZenaDrone 1000 can be deployed for search and rescue operations, firefighting, cargo delivery, and land surveys.

In addition, the Zendrone 1000 has seen interest from the U.S. Military, NATO partners, Irish farmers, the German police force, and the German rail. Earlier in spring, EPAZ announced plans for an expanded manufacturing facility that is expected to produce over 30 drones per month, ensuring efficient delivery to customers worldwide.

Shaun Passley, Ph.D., commented on the progress of ZenaDrone 1000 sales, stating, “We are thrilled to witness the development of our ZenaDrone 1000 sales pipeline as we work toward generating revenue from this venture.”

EPAZ: Intellectual Property

EPAZ is actively protecting its intellectual property by filing a series of patents for its drone technology and artificial intelligence innovations. The company has already received two patents for its drone technology, with two more currently under review by the US Patent Office. Epazz has also pursued international patents to safeguard its technological advancements globally.

Shaun Passley, Ph.D., emphasized the significance of protecting their intellectual property, stating, “We are taking our drone technology to new heights with the integration of artificial intelligence, and it’s crucial for us to safeguard our innovations.”

Through its subsidiaries, Galaxy Batteries Inc. and ZenaDrone Inc., EPAZ is driving groundbreaking advancements and positioning itself as a potential future leader in the market. With a commitment to protecting its intellectual property and a focus on delivering cutting-edge technologies, Epazz makes a great stock to watch for potential breakouts.

Skye Bioscience Inc. (OTC: SKYE) is a clinical-stage pharmaceutical company specializing in the development and commercialization of novel cannabinoid derivatives. The company’s primary focus is on modulating the endocannabinoid system, which plays a vital role in overall human health and has shown significant potential in multiple ocular indications.

Currently, Skye Bioscience is conducting a Phase 1 clinical trial for its lead product candidate, SBI-100 Ophthalmic Emulsion. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of SBI-100 OE, a cannabinoid receptor type 1 (CB1R) agonist administered topically to the eye. Additionally, the trial measures changes in intraocular pressure, a critical factor in ocular health.

With the recent completion of dosing for the third and final cohort of healthy volunteers, Skye Bioscience has achieved an important milestone in its Phase 1 clinical trial. The trial enrolled a total of 48 participants, with different dosing regimens being tested to assess the efficacy and safety of SBI-100 OE. Preliminary data from the trial indicated that SBI-100 OE was well tolerated, with no drug-related serious adverse events and only mild to moderate adverse events commonly associated with topically applied eye treatments.

As Skye Bioscience moves forward, the company anticipates providing a preliminary data report in Q3, which will shed more light on the trial’s outcomes and the potential of SBI-100 OE as a treatment for ocular indications, including glaucoma and ocular hypertension.

With its innovative approach to cannabinoid derivatives and a focus on ocular health, Skye Bioscience is positioned as an emerging player in the pharmaceutical industry. Investors and industry observers are eagerly awaiting further updates and data from the ongoing Phase 1 trial, recognizing the potential impact of Skye Bioscience’s research and development efforts in addressing unmet medical needs.

NaturalShrimp, Inc. (OTC: SHMP) is a biotechnology aquaculture company that specializes in shrimp cultivation. They have developed and patented the first commercially operational Recirculating Aquaculture System (RAS) specifically designed for shrimp production. 

Two weeks ago, SHMP announced they had signed a technology licensing agreement with Niterra Co., Ltd., a prominent manufacturer of spark plugs with a diverse portfolio spanning automotive, motorcycle, marine, and small engine applications.

Under the agreement, Niterra will have the opportunity to trial NaturalShrimp’s proprietary Electrocoagulation (EC) and Hydrogas technologies. These technologies are aimed at enhancing shrimp cultivation practices within small-scale, locally owned aquacultural farms in Japan. The trial period is expected to last approximately six months and will involve deploying the necessary equipment, including Electrocoagulation equipment, Hydrogas systems, water dosing equipment, connectors, and other essential components.

Niterra Ventures Company’s mission to pursue innovative solutions and tackle tomorrow’s challenges makes them an ideal partner for our technologies,’ said Gerald Easterling, CEO of  NaturalShrimp. ‘Niterra is the first company in Asia to license our technology, expanding our opportunity to provide fresh, naturally grown shrimp in one of the world’s largest seafood markets. We expect a successful initial trial that will lay the groundwork for additional agreements with different species. We look forward to building a strong collaborative relationship with Niterra as they explore how our easily controlled technologies electronically remove ammonia and nitrites, reduce the bacteria load, and improve the overall health of animals within an aquaculture system.’

SHMP is currently trading at $0.046 USD, reflecting a decrease of 0.52% as of 2 p.m. Wednesday.

Basanite Inc. (OTC: BASA) is a manufacturer and developer of sustainable composite construction materials. Their flagship product, BasaFlex, is an advanced alternative to steel reinforcement in concrete structures. 

Basanite Inc., through its subsidiary Basanite Industries, LLC, specializes in manufacturing environmentally friendly, high-performance basalt fiber composite products. These superior alternatives to traditional steel elements are gaining recognition for their strength, durability, and extended lifespan. 

Recently, BASA announced that it had achieved a significant milestone with the approval of its BasaFlexTM products by the Florida Department of Transportation. This recognition demonstrates Basanite’s commitment to meeting stringent quality assurance and control standards.

With its cutting-edge technology and the growing demand for sustainable construction materials, Basanite Inc. holds significant breakout potential. The approval from FDOT serves as a catalyst for market expansion and increased adoption of BasaFlex in infrastructure projects. By offering a game-changing solution that addresses corrosion issues and provides long-term cost savings, Basanite positions itself for success.

As Basanite Inc. progresses on its pathway to commercialization, investors may want to closely monitor the company’s performance. With its unique product offerings, commitment to quality, and potential for market disruption, Basanite Inc. is well-positioned to capture a significant share of the concrete reinforcement market.



Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Epazz Inc. to assist in the production and distribution of content. ‘CGR’  is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Please visit for full disclaimer.

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
Country: United States